Agilent Technologies, Inc. A
172.79
(0.05)
(0.03%)
as of 25 Sep
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Agilent Technologies, Inc. (A) P/S ratio
As of 25 September 2026, Agilent Technologies, Inc. (A) trades at a P/S ratio of 6.6×. Over the past ten years it has ranged from 2.3× (September 2015) to 8.8× (September 2021); the current reading is higher than 88% of that period. That is above the Diagnostics & Research industry median of 4.9× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 6.0× | 3.06% |
| FY2024 | 5.8× | 30.52% |
| FY2023 | 4.4× | (26.37%) |
| FY2022 | 6.0× | (20.05%) |
| FY2021 | 7.6× | 24.05% |
| FY2020 | 6.1× | 32.21% |
| FY2019 | 4.6× | 8.85% |
| FY2018 | 4.2× | (13.60%) |
| FY2017 | 4.9× | 44.91% |
| FY2016 | 3.4× | 6.22% |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jul 2026 | 5.3× | 17.47% |
| Apr 2026 | 4.5× | (16.92%) |
| Jan 2026 | 5.4× | (9.35%) |
| Oct 2025 | 6.0× | 24.54% |
| 43 more quarters | Free account |
Against its own ten years
Low 2.3×
High 8.8×
Ten-year median
5.0×
Current reading's percentile
88
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| DGX Quest Diagnostics Incorporated compare | 2.3× |
| IQV IQVIA Holdings Inc. compare | 2.6× |
| A Agilent Technologies, Inc. | 6.6× |
| MTD Mettler-Toledo International, Inc. compare | 7.4× |
| IDXX IDEXX Laboratories, Inc. compare | 9.0× |
| ILMN Illumina, Inc. compare | 9.2× |
| WAT Waters Corporation compare | 9.2× |
| GH Guardant Health, Inc. compare | 19.9× |
| NTRA Natera, Inc. compare | 21.8× |
| Diagnostics & Research industry median | 4.9× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on A
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement